Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fujifilm Eyes Avigan Use in Mild and Severe COVID-19 Cases: Exec
October 19, 2020
- Chinese Regulators Accept Eisai’s Fycompa for Monotherapy, Additional Pediatric Use
October 19, 2020
- (Update) Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Chugai, Roche Discussing Japan Development of Regeneron's COVID-19 Antibody Cocktail
October 16, 2020
- JPWA Raided Too over Big 4 Wholesalers’ Bid-Rigging Scandal
October 16, 2020
- Avigan Filed for COVID-19 in Japan: Fujifilm
October 16, 2020
- Evaluating Vaccine Efficacy Will Be a Challenge for COVID-19 Vaccine Development in Japan: Developers
October 16, 2020
- Chugai Files 1st Oral SMA Treatment in Japan
October 16, 2020
- Otsuka Misses Primary Goal in PIII Guadecitabine Trials
October 16, 2020
- Astellas to Snap Up US Implantable Medical Devices Startup iota
October 16, 2020
- Japan Sees Improved LHRH Agonist Supply as Leuprorelin Output Rises; Shipment Curbs for Substitutes Lifted
October 15, 2020
- Remicade Biosimilars Expand Labels into Ankylosing Spondylitis
October 15, 2020
- Takeda Links Arms with Accenture, AWS to Accelerate Digital Transformation
October 15, 2020
- Cefiderocol Demonstrated Non-Inferiority to Meropenem in Global PIII: Shionogi
October 15, 2020
- LEO Pharma, Hokkaido Univ. Pair Up to Identify Therapeutic Targets in Leukoplakia, Alopecia Areata
October 15, 2020
- Kyowa CritiCare Resumes Production of Soft Bag Products
October 14, 2020
- Shionogi Chief Says China JV Marks Pivot from Overly US-Focused Investments
October 14, 2020
- Big 4 Wholesalers Now Suspected to Have Rigged Drug Prices in 2016 Too
October 14, 2020
- Padcev Shows Positive PII Results for Urothelial Cancer Patients Ineligible for Cisplatin: Astellas
October 14, 2020
- Ono Licenses Epilepsy Med from South Korean Biopharma
October 14, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…